---
id: nosocomial-pneumonia-hap-vap_340
category: syndromes
tags: [HAP, VAP, hospital-acquired-pneumonia, ventilator-associated-pneumonia, Pseudomonas, MRSA, empiric-therapy]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP)

**Q:** What are the IDSA/ATS 2016 guidelines for empiric treatment and duration of HAP and VAP?

**A:**

**Definitions:**
- **HAP**: Pneumonia occurring ≥48 hours after hospital admission (not present at admission)
- **VAP**: Pneumonia occurring >48 hours after endotracheal intubation

**Empiric Antibiotic Coverage (IDSA/ATS 2016):**

All empiric regimens for HAP/VAP must cover:
1. **Staphylococcus aureus** (MRSA coverage if risk factors present)
2. **Pseudomonas aeruginosa**
3. Other gram-negative bacilli

| Risk Factors for MRSA/MDR | Empiric Coverage | Antibiotic Choices |
|----------------------------|------------------|-------------------|
| **MRSA Risk**: Prior IV antibiotics within 90 days, hospitalization in unit with >20% MRSA | **Anti-MRSA agent** | **Vancomycin** OR **linezolid** |
| **MDR Gram-Neg Risk**: Prior IV antibiotics within 90 days, septic shock, ARDS, ≥5 days hospitalization, acute renal replacement therapy | **Anti-pseudomonal β-lactam** PLUS **2nd gram-neg agent** | **β-lactam options:**<br>- Piperacillin-tazobactam 4.5 g IV q6h<br>- Cefepime 2 g IV q8h<br>- Ceftazidime 2 g IV q8h<br>- Aztreonam 2 g IV q8h<br>- Meropenem 1 g IV q8h<br><br>**PLUS 2nd agent:**<br>- Fluoroquinolone (levofloxacin, ciprofloxacin) OR<br>- Aminoglycoside (amikacin, gentamicin, tobramycin) |

**Key Principles:**
- **Local antibiograms**: Tailor empiric therapy based on local resistance patterns
- **De-escalation**: Narrow antibiotics based on cultures (sputum, BAL, mini-BAL)
- **Procalcitonin (PCT)**: Can guide antibiotic discontinuation (stop if PCT <0.1 ng/mL or 80% decrease)

**Treatment Duration (2024 Guidelines):**
- **Standard duration**: **7 days** (HAP/VAP)
- CAP: 5 days
- Good clinical response: Can stop at 7 days
- Poor response/complications: May extend to 10-14 days

**VAP Prevention (2024 ISID Position Paper):**
- Oral care with chlorhexidine
- Elevate head of bed 30-45°
- Daily sedation interruption and spontaneous breathing trials
- Avoid reintubation
- Selective digestive decontamination (SDD) in select centers

**Key Points:**
- **Empiric coverage**: Always cover MRSA (if risk factors) + Pseudomonas
- **Duration**: 7 days for most HAP/VAP (not 10-14 days)
- **De-escalation**: Narrow based on cultures and clinical response
- **Prevention**: Oral chlorhexidine, HOB elevation, minimize sedation

**Mnemonic - "HAP/VAP = Hospital Acquired Pneumonia/Ventilator = 7 days, Cover MRSA + Pseudomonas"**

**Pearl:** HAP/VAP empiric therapy must cover MRSA (vancomycin or linezolid) and Pseudomonas (anti-pseudomonal β-lactam ± 2nd gram-neg agent). Standard treatment duration is 7 days (NOT 10-14 days). De-escalate based on cultures. Procalcitonin can guide discontinuation. Prevention: chlorhexidine oral care, head of bed elevation, daily sedation interruption.

**Media:**

**Sources:** [IDSA/ATS 2016 HAP/VAP Guidelines], [PMC10820465 - HAP/VAP Literature Review 2024], [ISID VAP Prevention 2024], [Stanford HAP/VAP Clinical Pathway]
